Study on drug discount data reporting

Summary#

SB 2370 is a North Dakota law that requires a study; it does not create prescription-drug reporting requirements. During the 2025–26 interim, Legislative Management must study possible reporting by participants in the federal drug discount program and report findings, recommendations, and any proposed legislation to the 2027 Legislative Assembly. Its stated goal is to explore how reported data could support public policy that directly benefits North Dakota patients.

  • The study must consider which entities should report, including health care facilities, contract pharmacies, federally qualified health centers, drug manufacturers, pharmacy benefit managers, and health insurers.
  • It must consider what data to collect, how to report, compile, and share it, and issues of confidentiality and disclosure.
  • It must consider ways to enforce possible reporting rules, including civil penalties for failing to report. The law does not impose those rules or penalties.
  • The study must include input from and consultation with listed professional associations, state agencies, hospitals, health centers, pharmacies, and insurers.

What it means for you#

  • Potentially affected organizations: The law does not require any organization to report data now. It directs a study of whether reporting should be required of the listed types of entities.
  • Patients and the public: The law does not create a new patient service or guarantee that data will be made public or used in a particular way. It requires the study to examine how compiled data could be shared for patients’ benefit.
  • State government: Legislative Management must conduct the study during the 2025–26 interim and report its findings and recommendations, with any legislation needed to carry them out, to the next Legislative Assembly.

Money#

No cost information is in the available material.

  • The law requires a study but gives no cost estimate or staffing amount.
  • It does not establish a reporting system, set fees, or impose fines.

What is unclear#

  • The law does not decide which entities, if any, would have to report or what data they would have to provide.
  • It does not set rules for reporting, public access, confidentiality, or data security; these are topics for the study.
  • It does not establish reporting enforcement or civil penalties.
  • It does not specify how the study will handle competing views among the listed participants and organizations.

Case for#

  • A study could help lawmakers assess whether information from the federal drug discount program could support policies aimed at benefiting patients.
  • Considering different types of participants and possible data elements could help lawmakers examine what information would be useful before creating reporting rules.
  • The required consultation and review of confidentiality could help identify practical concerns before any reporting system is proposed.

Case against#

  • The law creates no reporting requirement or immediate change in what patients or organizations do; any policy change would require further action.
  • The study is tasked with examining broad questions, but the law does not set specific data goals or standards for judging which data would benefit patients.
  • A future reporting system could raise confidentiality concerns or impose costs, but the law does not settle how those concerns or costs would be addressed.

Votes

2 recorded votes on this bill, newest first.

  1. Division No. 1558397

    Passed45 members voted

    Senate Second reading

    FOR · 40AGAINST · 5

    Each dot is one member. Hover or tap one to see who.

    40For

    • Republican37
    • Democratic3

    5Against

    • Republican3
    • Democratic2

    2 members were paired and sat out the vote.

  2. Division No. 1498544

    Passed47 members voted

    Senate Second reading

    FOR · 47

    Each dot is one member. Hover or tap one to see who.

    47For

    • Republican42
    • Democratic5

    0Against